Karina Vera

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence et al. · European Journal of Cancer · 2010 · 167 citations

Medicine, Oncology, Pharmacology +12

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Catherine Delbaldo, Éric Raymond, Karina Vera et al. · Investigational New Drugs · 2007 · 101 citations

Pharmacy, Oncology, Pharmacokinetics +17

A Culturally Targeted Website for Hispanics/Latinos About Living Kidney Donation and Transplantation

Elisa J. Gordon, Joe Feinglass, Paula Carney et al. · Transplantation · 2015 · 84 citations

Medicine, Multicultural Education, Nephrology +17